Published in BioCentury on April 25, 2016 | Cover Story
Timeline visualizing the path to market of Clovis Oncology's Rociletinib to treat non-small cell lung cancer (NSCLC). Tumor in background image sits on timeline where things start to go awry on the drug's path to market, largely due to indecision on dosage.